Tag: spinal_muscular_atrophy
-
FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
FDA says postmarketing reports link Zolgensma to malignancies, including confirmed insertional oncogenesis involving the GLI1 gene, and warns the risk applies to Itvisma as well.
HealthScience & TechnologyPolitics and GovernmentMedical ScienceFederal GovernmentLegal ZolgensmaItvismaFood and Drug Administrationinsertional oncogenesisspinal muscular atrophygene therapyNovartisFood RecallsFDADrugs
-
Media Monitor: TIME Health Highlights Essay on Asking for Help, FDA Approval for SMA Drug
TIME Health is reporting on a psychologist's essay about the value of asking for help, plus FDA approval of a first-of-its-kind drug for spinal muscular atrophy and concerns over CDC information.
HealthMedical ScienceScience & TechnologyMediaUSA TIME HealthJoan M. CookYale School of Medicinespinal muscular atrophyFDACDCmeasles